
TailorMed Expands Solutions to Address Gaps in Access and Patient Adherence
Key Takeaways
- New-to-brand abandonment remains 35–40%, and PBM accumulator/maximizer designs blunt manufacturer copay support at dispensing, making affordability-only tools insufficient for sustained specialty therapy persistence.
- The IRA’s 2026 $2,100 Medicare Part D out-of-pocket cap does not resolve commercial access barriers, where prior authorization intensity and formulary exclusions continue expanding.
TailorMed broadens patient support beyond copay help, adding five modules that link access, affordability and adherence across specialty medications.
TailorMed has announced an expansion of its platform, moving beyond its origins as a medication affordability solution to offer a broader suite of tools aimed at the full continuum of patient support, from initial prescription access through long-term adherence.
The company unveiled what it is calling the
Why Affordability Alone No Longer Solves the Patient Access Problem
The announcement reflects growing industry recognition that financial assistance alone is insufficient to keep patients on specialty therapies. As Pharmaceutical Commerce has covered previously,
What Is the TailorMed Medication Affordability Solutions Network?
TailorMed's expanded platform attempts to address these layered challenges through a coordinated architecture. TailorMed Core is a care team-facing tool that automates the lifecycle of patient support programs; TailorMed Connect is a patient-facing app featuring a copay wallet for real-time financial assistance access; TailorMed Complete combines that automation with tech-enabled human support services; TailorMed Amplify distributes life sciences programs digitally across the network; and TailorMed Alliance is designed to extend reach through third-party partner integration.
"Affordability is a huge problem and remains at the heart of what we do," said CEO Srulik Dvorsky. "But for patients, it's rarely the only challenge."
How Specialty Pharmacy Is Evolving to Address Cost, Access, and Adherence Together
That sentiment aligns with a broader shift the industry has been navigating. Specialty pharmacies are increasingly expected to function as clinical coordinators—centralizing access to copay and charitable foundation options while providing clinical specialists to support both patients and prescribers. The intersection of cost, access, and adherence is no longer treated as three separate problems, and vendors operating at only one of those layers face growing pressure to expand their scope or risk being displaced by more integrated offerings.
TailorMed's Network Scale and What It Means for Manufacturer Programs
TailorMed's scale is notable context for the expansion. The company reports that its network now reaches 335 million prescriptions annually and has facilitated more than $7.4 billion in patient financial assistance since 2020. Whether that breadth translates into commercial leverage for the new modules—particularly TailorMed Amplify, which positions the platform as a distribution channel for manufacturer-sponsored programs—will be closely watched by hub services competitors and pharma brand teams alike.
The Bottom Line for Pharma Manufacturers
For pharma manufacturers managing specialty portfolios, the practical question is whether a single-vendor platform addressing affordability, access, and adherence simultaneously can outperform specialized point solutions at each stage or whether the growing complexity of the patient support landscape demands precise integration.




